Trade Incyte Corporation - INCY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.30 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 58.85 |
| Open | 58.09 |
| 1-Year Change | 12.32% |
| Day's Range | 57.88 - 59.05 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 58.85 | 1.40 | 2.44% | 57.45 | 58.97 | 57.10 |
| Apr 23, 2025 | 57.91 | -0.19 | -0.33% | 58.10 | 58.94 | 57.56 |
| Apr 22, 2025 | 57.28 | -0.19 | -0.33% | 57.47 | 57.55 | 56.64 |
| Apr 21, 2025 | 56.71 | -0.45 | -0.79% | 57.16 | 58.16 | 55.97 |
| Apr 17, 2025 | 58.08 | 0.38 | 0.66% | 57.70 | 58.37 | 56.55 |
| Apr 16, 2025 | 57.67 | -0.58 | -1.00% | 58.25 | 58.54 | 56.99 |
| Apr 15, 2025 | 58.31 | -0.09 | -0.15% | 58.40 | 59.87 | 58.02 |
| Apr 14, 2025 | 59.14 | 2.07 | 3.63% | 57.07 | 59.20 | 56.73 |
| Apr 11, 2025 | 56.79 | 1.44 | 2.60% | 55.35 | 56.91 | 54.68 |
| Apr 10, 2025 | 54.95 | -2.69 | -4.67% | 57.64 | 57.67 | 53.62 |
| Apr 9, 2025 | 58.73 | 3.26 | 5.88% | 55.47 | 59.26 | 53.43 |
| Apr 8, 2025 | 56.68 | -3.66 | -6.07% | 60.34 | 61.01 | 55.96 |
| Apr 7, 2025 | 60.21 | 0.88 | 1.48% | 59.33 | 60.94 | 57.23 |
| Apr 4, 2025 | 59.67 | -2.74 | -4.39% | 62.41 | 63.38 | 59.67 |
| Apr 3, 2025 | 62.28 | 1.25 | 2.05% | 61.03 | 62.77 | 61.03 |
| Apr 2, 2025 | 62.25 | 2.08 | 3.46% | 60.17 | 62.42 | 60.17 |
| Apr 1, 2025 | 60.83 | 0.56 | 0.93% | 60.27 | 61.90 | 59.89 |
| Mar 31, 2025 | 60.27 | 0.56 | 0.94% | 59.71 | 60.73 | 59.03 |
| Mar 28, 2025 | 60.52 | 0.34 | 0.56% | 60.18 | 60.85 | 60.18 |
| Mar 27, 2025 | 60.55 | -0.67 | -1.09% | 61.22 | 61.40 | 60.07 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Incyte Company profile
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares
| Industry: | Biopharmaceuticals |
1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com